Long-term response to regorafenib (REG) in patients with metastatic colorectal cancer (mCRC): A systematic literature review (SLR)

被引：0
|
作者：
Peeters, M. [1 ]
Pan, X. [2 ]
Koufopoulou, M. [3 ]
Arregui, M. [4 ]
Wissinger, E. [5 ]
Ostojic, H. [6 ]
Pisa, F. [7 ]
Kim, R. D. [8 ]
机构：
[1] Univ Hosp Antwerp, Ctr Oncol Res, Edegem, Belgium
[2] Bayer Healthcare Pharmaceut Inc, Real World Evidence Oncol, Whippany, NJ 07981 USA
[3] Cencora, Evidence Generat & Value Commun, London, England
[4] Cencora, Evidence Generat & Value Commun, Hannover, Germany
[5] Cencora, Evidence Generat & Value Commun, Conshohocken, PA USA
[6] Bayer Consumer Care AG, Global Med Affairs, Basel, Switzerland
[7] Bayer AG, Real World Evidence Oncol, Berlin, Germany
[8] H Lee Moffitt Canc Ctr & Res Inst, Gastrointestinal Oncol, Tampa, FL USA
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.05.075
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
64P
引用
收藏
页码：S30 / S31
页数：2
相关论文
共 50 条
  • [41] Molecular subtypes and outcomes in regorafenib-treated patients with metastatic colorectal cancer (mCRC) enrolled in the CORRECT trial
    Karthaus, M.
    Schwenke, S.
    Seidel, H.
    Beckmann, G.
    Reischl, J.
    Vonk, R.
    Lenz, H. -J
    Tebernero, J.
    Siena, S.
    Grothey, A.
    van Cutsem, E.
    Jeffers, M.
    Wagner, A.
    Laurent, D.
    Kobina, S.
    Rutstein, M.
    Guinney, J.
    Tejpar, S.
    Oncology Research and Treatment, 2015, 38 : 57 - 58
  • [42] Characteristics and outcomes of patients enrolled in the CORRECT and CONCUR phase 3 trials of regorafenib for metastatic colorectal cancer (mCRC)
    Vogel, A.
    van Cutsem, E.
    Wagner, A.
    Kalmus, J.
    Qin, S.
    Kim, T. W.
    Li, J.
    Xu, R.
    Grothey, A.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 71 - 71
  • [43] Molecular subtypes and outcomes in regorafenib-treated patients with metastatic colorectal cancer (mCRC) enrolled in the CORRECT trial
    Teufel, Michael
    Schwenke, Susanne
    Seidel, Henrik
    Beckmann, Georg
    Reischl, Joachim
    Vonk, Richardus
    Lenz, Heinz-Josef
    Tabernero, Josep
    Siena, Salvatore
    Grothey, Axel
    Van Cutsem, Eric
    Jeffers, Michael
    Wilhelm, Scott
    Wagner, Andrea
    Laurent, Dirk
    Kobina, Svetlana
    Rutstein, Mark Daniel
    Wirapati, Pratyaksha
    Guinney, Justin
    Tejpar, Sabine
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [44] Long-Term Treatment of Metastatic Colorectal Cancer with Panitumumab
    Lopez-Gomez, Miriam
    Merino, Maria
    Casado, Enrique
    CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2012, 6
  • [45] Sequential treatment with regorafenib (REG) and trifluridine/tipiracil (TAS) plus /- bevacizumab (Bev) in refractory metastatic colorectal cancer (mCRC) in community clinical practice in the USA
    Bekaii-Saab, T.
    Ahn, D.
    Yuan, C.
    Jiao, X.
    Kurtinecz, M.
    Pan, X.
    Vassilev, Z.
    Ostojic, H.
    ANNALS OF ONCOLOGY, 2023, 34 : S442 - S442
  • [46] A SYSTEMATIC LITERATURE REVIEW TO IDENTIFY TRIALS IN FIRST-LINE RAS WILD-TYPE (WT) METASTATIC COLORECTAL CANCER (MCRC) PATIENTS
    Jarrett, J.
    Weijers, L.
    Hnoosh, A.
    Harty, G.
    von Hohnhorst, P.
    VALUE IN HEALTH, 2014, 17 (07) : A617 - A617
  • [47] Real-world adherence and treatment discontinuation with trifluridine/tipiracil (FTD-TPI) compared with regorafenib (REG) for the treatment of metastatic colorectal cancer (mCRC).
    Patel, Anuj K.
    Duh, Mei Sheng
    Barghout, Victoria E.
    Yenikomshian, Mihran Ara
    Xiao, Yongling
    Wynant, Willy
    Tabesh, Majid
    Fuchs, Charles S.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [48] Burden of illness of HER2+in metastatic breast cancer (MBC) patients: A systematic literature review (SLR)
    Vondeling, G.
    Harding, T.
    Seddik, A.
    Bakker, K.
    Velikanova, R.
    ANNALS OF ONCOLOGY, 2021, 32 : S490 - S490
  • [49] Long-term treatment with bevacizumab for patients with metastatic colorectal cancer: Case report
    Hurwitz, Herbert I.
    Honeycutt, Wanda
    Haley, Sherri
    Favaro, Justin
    CLINICAL COLORECTAL CANCER, 2006, 6 (01) : 66 - 69
  • [50] A comparison of regorafenib and fruquintinib for metastatic colorectal cancer: a systematic review and network meta-analysis
    Jing, Zhu
    Rui, Zhou
    Zhang binglan
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2019, 145 (09) : 2313 - 2323
12345